MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Protect from light and moisture. Store in an airtight container.

Provenance

This compatibility recommendation is derived from Imodium IBS Relief 2mg capsules (McNeil Products Ltd).

Stability Notes

Should be stored in tight, light resistant containers and protected from excessive moisture.

Provenance

This compatibility recommendation is derived from Clarityn Allergy 10mg tablets (Bayer Plc) and Loratadine 10mg tablets (Accord Healthcare Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Fluconazole 150mg capsules (Accord Healthcare Ltd), Fluconazole 150mg capsules (Kent Pharma (UK) Ltd) and Diflucan 150mg capsules (Pfizer Ltd).

Stability Notes

Store in an airtight container. Max 7 days in MCA.

Legislation states unless there are exceptional circumstances, valproate-containing medicines must always be dispensed in the manufacturer’s original full pack. The Patient Information Leaflet should be provided.

Provenance

This compatibility recommendation is derived from Depakote 250mg gastro-resistant tablets (Sanofi).

Stability Notes

Store in an airtight container. Max 7 days in MCA.

Legislation states unless there are exceptional circumstances, valproate-containing medicines must always be dispensed in the manufacturer’s original full pack. The Patient Information Leaflet should be provided.

Provenance

This compatibility recommendation is derived from Depakote 500mg gastro-resistant tablets (Sanofi).

Stability Notes

Protect from light and moisture. Store in airtight containers.

Provenance

This compatibility recommendation is derived from generic cetirizine 10mg tablets.

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.